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http://dx.doi.org/10.1016/j.fjs.2013.Summary Cervical total disc replacement (CTDR) has been accepted as a viable option for
surgical management of cervical spondylosis or degenerative disc disease. Current indications
for CTDR are one- and two-level cervical spondylosis and degenerative disc disease causing ra-
diculopathy or myelopathy that is refractory to medical treatment. Conventionally, these pa-
tients could be managed surgically with anterior cervical discectomy and fusion (ACDF) as the
standard of care. In recent years, there have been several large-scale, prospective, random-
ized, and controlled clinical trials that have demonstrated similarly excellent clinical out-
comes of both CTDR and ACDF for one-level cervical degenerative disc disease with 5 years
of follow-up. Because CTDR allows preservation of segmental motion of the spine and has
the potential to reduce the risk of adjacent segment disease (ASD), it has gained popularity
in recent years. However, the surgical technique of CTDR is more demanding, and associated
complications have been reported. Furthermore, the true effect of CTDR on the incidence of
ASD remains uncertain. Therefore, further investigations are required to corroborate favorable
long-term results, and whether CTDR can reduce the risk of ASD. Appropriate patient selection
and accurate surgical techniques remain the fundamentals of a successful CTDR. The currently
available data suggest that CTDR is a safe and effective alternative to ACDF to treat patients
with cervical spondylosis or degenerative disc disease and meet the criteria of clinical trials.
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50 J.-C. Wu1. Rationale
Anterior cervical discectomy and fusion (ACDF) has been
accepted as the gold standard of surgical management for
cervical spondylosis and disc disease causing radiculopathy
or myelopathy. High patient-satisfaction scores and high
arthrodesis rates associated with ACDF have been reported
in the literature.1 However, there is always the concern of
loss of segmental motion at the index level of the inter-
vertebral disc after ACDF. Furthermore, adjacent segment
disease (ASD) has been reported after cervical fusion at a
rate of 2.9% per year.2 This development of ASD may also
cause symptoms that require re-operations.2e4 A study
from Taiwan, covering 19,385 patients who underwent
ACDF over a period of 11 years, estimated the incidence of
ASD that required a repeat ACDF operation to be 0.8%
annually.4 Although the actual etiology of re-operation for
ASD after ACDF is still uncertain, it can be attributed to the
natural course of spondylosis or a consequence of increased
load after neighboring arthrodesis. Wu et al reported that,
in Taiwan, after ACDF, a considerable portion (i.e., 5.6%) of
patients had a second ACDF during the following 10 years.4
In recent years, there has been an emerging option of
cervical total disc replacement (CTDR) for surgical man-
agement of disc disease in the cervical spine. The devel-
opment of CTDR intends to preserve motion and reduce
ASD. By implantation of an artificial disc instead of a bone
graft after cervical discectomy, the technology of CTDR
allows preservation of spinal motion at the indexed inter-
vertebral disc (Fig. 1). In theory, maintaining the segmental
motion at the indexed disc level translates little workloadFigure 1 Postoperative dynamic radiographs. The patient underw
cervical radiculopathy. Postoperative lateral radiographs demonstrto the neighboring discs and might thus reduce the inci-
dence of ASD. From reports of short- to mid-term (i.e., 2e5
years) follow-up, the average range of motion at the index
level was successfully preserved at approximately 8 after
CTDR.5e8 However, the reduction in ASD or avoidance of a
second surgical procedure for ASD was uncertain in these
reports. Whether ASD could be ameliorated still needs data
from long-term follow-up to validate.
2. Clinical trials
There are several prospective, randomized, controlled,
multicenter clinical trials, approved by the U.S. Food and
Drug Administration (FDA) investigational device exemption
(IDE), comparing CTDR with ACDF for single-level cervical
disc disease with more than 2e5 years of follow-up.5e7,9,10
These trials have analyzed outcomes of a number of arti-
ficial disc devices (e.g., BRYAN, Prestige ST, ProDisc-C, and
KineflexjC) with a comparison to instrumented ACDF in the
management of one-level cervical disc disease. All these
trials have applied similar inclusion and exclusion criteria,
used similar radiological and clinical outcome measure-
ments, and had their data published in major journals.
3. Indications
The inclusion criteria of the aforementioned FDA-IDE trials
for CTDR were adult patients with single-level symptomatic
cervical spondylosis and disc herniation at C3eC7 levels
who presented with intractable radiculopathy, myelopathy,ent cervical total disc replacement for a herniated disc causing
ated the preserved segmental motion at C5/C6.
Cervical TDR 51or neck pain. The best candidates for CTDR should be young
patients who have radiculopathy caused by herniated disc
with competent facet joints. In current practice, the
generally accepted indications for CTDR are one- or two-
level cervical disc herniation, degenerative disc disease,
and spondylosis (Table 1).
The relative contraindications for CTDR are kyphotic
deformity, severe spondylosis with incompetent facet
joints, trauma-related ligamentous or facet injury, osteo-
porosis, and cervical ankylosis. In addition, there are re-
ports analyzing the outcomes of patients undergoing CTDR
for slightly different indications, failing to demonstrate
significant differences.11e13 Although the inclusion criteria
in the published FDA-IDE trials included patients with
myelopathy, the actual effect of CTDR on cervical spon-
dylotic myelopathy remains uncertain. Furthermore,
several clinical series revealed the efficacy of CTDR in
multilevel cervical spondylosis or disc disease.11,12,14,15
However, only scarce reports have compared multilevel
CTDR with ACDF.4. Outcomes
A combined analysis of three major FDA-IDE trials revealed
that segmental sagittal motion was preserved with CTDR
(preoperatively 7.26 and postoperatively 8.14) 2 years
after surgery.8 By contrast, in these trials, ACDF aimed to
achieve arthrodesis (i.e., to stop motion) and had a fusion
rate of 95% at 2 years postoperatively. Similarly, in these
published FDA-IDE trials, both ACDF and CTDR demon-
strated excellent 2e5-year clinical outcomes for the
treatment of one-level cervical disc disease.5e10,16e18
There was little difference in relief of symptoms and
improvement of neurological functions between CTDR and
ACDF. The effect of this new technology of CTDR is likely to
be equivalent to that of the standard care of management
of ACDF. Therefore, CTDR has become a viable and effec-
tive option for surgical management of spondylosis and disc
herniation.
The actual effect of CTDR on ASD, however, remains
uncertain. Upadhyaya et al reported a combined analysis of
three major FDA-IDE trials composed of a total of 1213
patients with a follow-up for 2 years.8 By analyzing these
randomized control trials, they concluded that CTDR is
associated with a lower rate of secondary surgery and a
higher rate of neurological success, and CTDR may be
associated with a lower rate of ASD at 2 yearsTable 1 Accepted indications and contraindications for
cervical total disc replacement.
Indications
One- or two-level cervical disc herniation
One- or two-level cervical spondylosis or degenerative
disc disease
Contraindications
Kyphotic deformity
Facet joint injury or diseases (incompetent facets)
Severe spondylosis causing ankylosis
Osteoporosispostoperatively. However, the concern of ASD requires a
long-term follow-up and a larger number of patients to
validate.8 None of the FDA-IDE trials has proven less ASD
after CTDR than ACDF in the management of one-level
cervical disc disease. Although it is intuitive to infer the
reduction of ASD by CTDR, from the best currently available
data, there have not been enough data to support protec-
tion against ASD by CTDR.
5. Complications
There are reports of complications associated with CTDR.
Using the same surgical approach, all the approach-related
complications associated with ACDF also apply to CTDR.
The most commonly seen and self-limiting complications
are hoarseness, dysphagia, and C5 palsy. Specific compli-
cations associated with CTDR are heterotopic ossification,
split fracture of the adjacent vertebral body, and migration
of the arthroplasty device.11,19e21 There are also reports on
hypersensitivity to the metal ions after CTDR.22,23 These
complications could be related to the surgical technique,
patient selection, or design of the device. As CTDR gains
more popularity, more reports of complications are
expected.
6. Technical pearls
Patient selection remains the cornerstone of successful
CTDR. Technically, the procedure of CTDR is more
demanding than ACDF. Both complete decompression of the
neural tissue and precise installation of the artificial disc
are required to restore the joint function. It is recom-
mended to decompress bilateral neural foramina directly
on both sides, including even the asymptomatic side to
achieve neurological success. ACDF eliminates segmental
motion and allows indirect decompression by increasing the
height of the neural foramen when the bone graft is
incorporated into the adjacent vertebral bodies. By
contrast, CTDR preserves motion; thus, in extreme flexion
or extension, inadequately decompressed foraminal
osteophytes could cause nerve root impingement. More-
over, it is our routine to resect the posterior longitudinal
ligament and both uncovertebral joints so that the teth-
ering of the exiting nerve roots or thecal sac can be avoided
during movement of the artificial disc (Table 2).
It is also reasonable to infer that the carpentry of CTDR
is critical for preservation of the physiological range of
motion. It is reported that the optimally performed CTDR
has better motility and less heterotopic ossification than
the suboptimal ones.21 There are several key elements in
common regardless of the design of the artificial discs,
including proper patient positioning, meticulous end-plate
preparation, appropriate sizing of the artificial disc (e.g.,
width, depth, and height), and accurate installation of the
device (e.g., alignment and centering).
7. Prospective
In neurosurgical practice, ACDF yields one of the highest
patient satisfaction rates among all the procedures with
Table 2 Pearls of surgical techniques.
Appropriate position of the neck (neutral or slightly
extended)
Bilateral decompression of neural foramen (resection
of uncovertebral joints)
Decompression of thecal sac (resection of posterior
longitudinal ligament)
Meticulous end-plate preparation (resection of marginal
osteophytes)
Precise sizing of artificial disc (adequate footprint
coverage and disc height)
Accurate installation (centering and alignment)
Copious irrigation (elimination of bone dust)
52 J.-C. Wusame or similar purposes. The emerging technology of CTDR
has the potential to further improve the surgical manage-
ment of cervical spondylotic disc disease. Although some of
the indications of ACDF and CTDR are overlapping, CTDR
could never totally replace ACDF. Currently, CTDR is an
option for the preservation of segmental motion of the
spine in highly selected patients. Although CTDR has gained
popularity in recent years, the long-term clinical results
and the goal of protection against ASD still need to be
validated. More studies with long-term follow-up are
necessary to corroborate the efficacy of CTDR.
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